Juventas
Updated: January 21, 2026
Lyu Lulu - CEO
Country: China | Funding: $101.6M (+)
Founded: 2018
Website: http://www.juventas.cn/en.php
Juventas develops and manufactures cellular immunotherapies for the treatment of cancer. The company has more than 10 drug candidates, including innovative single- and multi-targeted therapies and general cell therapy products. Its flagship candidate, Inaticabtagene Autoleucel, is the first CAR-T therapy targeting CD19 in China. It is undergoing clinical trials for the treatment of relapsed and refractory acute lymphoblastic leukemia in adults, relapsed and refractory aggressive B-cell non-Hodgkin's lymphoma, and B-cell acute lymphoblastic leukemia in children and adolescents. It has received Breakthrough Therapy designation from the Center for Drug Evaluation from China's NMPA and Orphan Drug designation from FDA.
Founded: 2018
Website: http://www.juventas.cn/en.php
Juventas develops and manufactures cellular immunotherapies for the treatment of cancer. The company has more than 10 drug candidates, including innovative single- and multi-targeted therapies and general cell therapy products. Its flagship candidate, Inaticabtagene Autoleucel, is the first CAR-T therapy targeting CD19 in China. It is undergoing clinical trials for the treatment of relapsed and refractory acute lymphoblastic leukemia in adults, relapsed and refractory aggressive B-cell non-Hodgkin's lymphoma, and B-cell acute lymphoblastic leukemia in children and adolescents. It has received Breakthrough Therapy designation from the Center for Drug Evaluation from China's NMPA and Orphan Drug designation from FDA.
